Ipamorelin

Ipamorelin is a research peptide studied in growth-hormone signalling and postoperative gut recovery. That research does not establish ligament-repair or general recovery benefits for an IP5-labelled product.

Early researchResearch added: 29 October 2026

Check the identity first.

IP5 is a market shorthand, not an independently verified medicine identity.

Why the interest?

IP5 may be presented as ipamorelin, but the shorthand is not proof of identity.

Growth-hormone signalling

Claims you may come across

Reported benefits, not product promises

Improved recovery, muscle gain and body composition.
Increased growth-hormone release.

Personal stories are anecdotal. They cannot show whether a product caused a change, how often it happens or what the risks are.

How much is backed up?

A controlled human study found a short growth-hormone response. That does not establish general recovery, muscle-building, or long-term health benefits, and it does not verify an IP5 product.

Research context: Gobburu et al. (1999): Pharmacokinetic-pharmacodynamic modelling of ipamorelin

Ipamorelin: hormones & recovery

Ipamorelin acts on the ghrelin receptor and can prompt the body to release growth hormone. IP5 is a market shorthand and cannot verify that an item contains ipamorelin, its formulation or any clinical benefit.

1999: a short growth-hormone response

A randomised dose-escalation study in healthy male volunteers measured ipamorelin and growth hormone in blood. The researchers’ model showed one short burst of growth hormone, peaking at about 40 minutes and falling to negligible levels by six hours. This demonstrates acute hormone signalling, not improved recovery, strength or long-term health.

Gobburu et al., Pharmaceutical Research (1999): Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers

2014: a negative bowel-surgery trial

A multicentre, double-blind phase II trial enrolled 117 adults having small or large bowel resection; 114 were included in the safety and modified intention-to-treat analyses. Median time to a first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, but the difference was not statistically significant, with p = 0.15.

Beck et al., International Journal of Colorectal Disease (2014): Ipamorelin for postoperative ileus in bowel resection patients

What this tells us

Evidence supports an acute growth-hormone signalling effect in a controlled study, but the cited surgical trial did not establish a postoperative recovery benefit. It does not support general recovery claims for IP5.

What’s being studied?

Growth-hormone signallingPostoperative gastrointestinal recovery in a completed phase II study

Research topics are not a promise of benefits.

What we know

Medsafe explicitly lists ipamorelin among products promoted online in its 2026 advisory.

What we don’t know

IP5 does not prove the contents are ipamorelin, or establish product quality, safety, clinical benefit or a lawful supply route.

Risks worth understanding.

Hormonal effects and interactions
Unknown long-term effects outside the studied setting
Contamination or non-sterility if injectable

This is not a complete list of risks or a personal safety assessment.

Already have a product?

Keep its packaging and ingredient information. Check the formulation, instructions and supplies together. An unidentified product cannot be made safe by an online dose calculation.

Before mixing: checks & supplies

Context matters.

Medsafe says unapproved products outside the regulated medicines system are illegal and potentially harmful.

“Research purposes only” is not a legal exemption or a safety guarantee. This guide is for research and educational purposes only and does not recommend taking this substance.

Read Medsafe’s warning

Common questions

The things you might be wondering.

What is ipamorelin?

It is a peptide researched for effects on growth-hormone signalling.

Does IP5 prove a product is ipamorelin?

No. A shorthand label cannot verify contents or strength.

Is there a safe dose I can use?

There is no universal safe dose. The completed trial does not establish a consumer protocol; discuss any treatment with a clinician and a confirmed regulated product.

Read it at the source.

Keep the conversation going

Two perspectives on the wider peptide conversation. These episodes provide context; they do not identify or validate a product with this label. Pick a thumbnail to watch here.

Huberman Lab · 1 April 2024

Peptide Benefits & Risks with Andrew Huberman

A useful starting point for the peptide conversation. Andrew Huberman talks through repair-related peptides, growth-hormone pathways and PT-141, alongside sourcing, side effects and the limits of the evidence. Listen for the difference between a promising idea and a result tested in people.

Play loads the YouTube player. Podcast discussion is context, not medical advice.

Episode & transcript

Huberman Lab · 1 June 2026

Peptide Science & Safety with Dr Abud Bakri

Why are peptides getting so much attention? Dr Abud Bakri joins Andrew Huberman to discuss BPC-157, GHK-Cu, melanotan and GLP-1 medicines. They explore what is being studied, why product sourcing matters and where animal findings still need to be tested in humans.